• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Antibodies
3. Mammalian antibody classes
4. Mammalian antibody classes (schematic)
5. Mammalian antibody subclasses
6. Monoclonal antibodies as therapeutic agents
7. IgG is the preferred class
8. Crystal structure of whole IgG2a
9. Antibody modes of action
10. Fc receptors - introduction
11. Fc receptors
12. Characteristics of human IgG Fc receptors
13. Human IgG Fc receptors
14. Cell distribution and expression of FcR
15. Cell activation by immune complexes
16. Cell inhibition by immune complexes
17. IgG1-FcRIII complex crystal structure
18. The Brambell receptor or FcRn
19. The IgG receptor FcRn
20. Effect of half-life on antibody concentration
21. Pathogen encoded HSV-1 FcR
22. Binding of human IgG to cells infected with HSV-1
23. Binding of human IgG1 allotype variants to cells
24. Human IgG glycosylation effect on binding to cells
25. IgG1 allotypes and HSV-1 FcR binding
26. IgG1 allotypes
27. Effector functions and therapy
28. Rodent monoclonal antibodies for therapy
29. Effector functions of rodent antibodies (ADCC)
30. Effector functions of rat antibodies
31. Campath-1 CD52 antigen
32. Therapeutic use of Campath-1(CD52) antibodies
33. Therapy with rat CD52 antibodies
34. Serotherapy with rat IgG2b Campath-1G
35. Mechanism of action of Campath-1G Ab
36. Problems with use of rodent antibodies for therapy
37. Human antibodies for therapeutic applications
38. Humanizing the rat IgG2b Campath-1G antibody
39. Effector functions of human isotypes
40. Rat IgG2b is effective in therapy
41. Human IgG1 also effective in therapy
42. Effector functions of human IgG
43. Summary
44. Acknowledgements

Topics Covered

• Antibody classes and subclasses
• General Ab structure
• Modes of action
• Fc receptors
• General FcR structures
• Cellular expression
• Triggering by immune complexes
• Neonatal FcR
• Antibody half-life
• Viral FcR
• Antibody allotypes
• Therapeutic use of monoclonal antibodies
• Mechanisms of action
• Antiglobulin responses
• Antibody humanization

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007

Financial Disclosures

• Requested.